ESTRO 2025 - Abstract Book

S1597

Clinical – Mixed sites & palliation

ESTRO 2025

Most common target sites were lungs (37.3%), nodes (30.3%) and bones (25.5%). Most common primary malignancies were prostate (41.4%) and lung (22.9%). SRS was delivered with volumetric modulated arc radiotherapy (VMAT) using a Simultaneous Integrated Boost (SIB) approach. Median prescribed dose was 28 Gy to Planning Target Volume (PTV) and 32 Gy to Internal Target Volume (ITV) for lung metastases, 16 Gy to PTV and 22 Gy to Gross Tumor Volume (GTV) for node lesions, and 16 Gy to PTV and 20 Gy to GTV for bone lesions (figure 1).